RWE 201 – Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development
Australia has several real-world evidence (RWE) initiatives to support healthcare and drug development. The Therapeutic Goods Administration (TGA) has established a framework for the use of real-world data (RWD) and RWE in regulatory decision-making, which includes the use of data from electronic health records and disease registries [1]. Following the 2021 Review into the usage of RWE and patient-reported outcomes (PROs) in the regulation of medicines and medical devices, the TGA has been working on incorporating RWE and PROs into its regulatory processes [2][3][4].
Additionally, the Medicines Intelligence Centre of Research Excellence (MI-CRE) was established to generate timely research supporting the evidentiary needs of Australian medicines regulators and payers by accelerating the development and translation of RWE on medicines use and outcomes [4]. MI-CRE aims to equip the next generation of medicines researchers in Australia with the skills to co-create evidence with end-users [5].
Despite these initiatives, there are still challenges and gaps in Australia’s RWE landscape. A review on generating RWE on the quality use, benefits, and safety of medicines in Australia highlights the need for a roadmap to bolster Australia’s capacity to accelerate evidence development about the effectiveness, safety, and quality use of medicines in routine clinical care [6]. Robust RWE generation requires current data roadblocks to be remedied as a matter of urgency to deliver efficient and equitable healthcare and improve the health and well-being of all Australians [6].
References:
[1] https://globalforum.diaglobal.org/issue/may-2023/rwd-rwe-in-2023-regulatory-policy-world-tour/
[2] https://www.tga.gov.au/real-world-evidence-rwe-and-patient-reported-outcomes-pros
[4] https://www.sciencedirect.com/science/article/pii/S0149291822000170
[5] https://ijpds.org/article/view/1726
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707536/
Share this story...
Real World Evidence (RWE) 201 – France – CNIL Regulatory Sandbox: Digital Health
RWE 201 - France – CNIL Regulatory Sandbox: Digital Health The French Data Protection Agency (CNIL) has been actively supporting digital health technology innovators through its regulatory "sandbox." These [...]
Real World Evidence (RWE) 201 – France – CNIL Reference Methodologies: Facilitating Access to Real World Data
RWE 201 - France – CNIL Reference Methodologies: Facilitating Access to Real World Data The CNIL (Commission Nationale de l'Informatique et des Libertés) is the French [...]
Real World Evidence (RWE) 201 – France – Health Data Hub: Facilitating Access to Real World Data
RWE 201 - France – Health Data Hub: Facilitating Access to Real World Data The purpose of France's Health Data Hub (HDH) is to facilitate the [...]
Real World Evidence (RWE) 201 – Canada – Health Canada’s position on the CADTH Guidance for Reporting RWE to Support Decision-making
RWE 201 - Canada – Health Canada’s position on the CADTH Guidance for Reporting RWE to Support Decision-making Health Canada released its position (May 2023) on [...]
Real World Evidence (RWE) 201 – Canada – Methods and Guidelines for Reporting Real World Evidence
RWE 201 - Canada – Methods and Guidelines for Reporting Real World Evidence Guidance for Reporting Real-World Evidence (RWE) [published May 2023] is a comprehensive document developed by the [...]
Real World Evidence (RWE) 201 – Health Canada’s 15 Key Elements for Protocol Development
RWE 201 - Health Canada's 15 Key Elements for Protocol Development Health Canada acknowledges that RWE can be particularly useful in areas where conducting controlled clinical trials is challenging [...]
